Who Stands To Gain With FDA Approval Of OTC Lipitor?
However, insurance companies will also be big winners, as medical insurance doesn’t cover OTC medications. Insurers will no longer need to pay for 10mg Lipitor prescriptions and, eventually, 10 mg generic atorvastatin prescriptions as well. Furthermore, in all likelihood, insurers will lobby hard to convert as many statin users as possible to OTC Lipitor. In doing so, they will perhaps shift as much as $1 billion of costs that they now have onto consumers. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - March 4, 2014 Category: Pharmaceuticals Authors: John LaMattina Source Type: news

Pfizer Starts Testing For Over-The-Counter Lipitor
Looking backward to improve its future, Pfizer will once again try to gain FDA approval to market its blockbuster drug, atorvastatin (Lipitor), over-the-counter (OTC). Peter Loftus reports in the Wall Street Journal that the company has started a clinical study to support the application for low-dose atorvastatin (10 mg). (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - March 3, 2014 Category: Pharmaceuticals Authors: Larry Husten Source Type: news

Pfizer Moves to Prop Up Lipitor
Pfizer hopes to overcome skepticism that consumers can appropriately take an over-the-counter version of cholesterol pill Lipitor without doctor guidance. (Source: WSJ.com: Health)
Source: WSJ.com: Health - March 3, 2014 Category: Pharmaceuticals Tags: FREE Source Type: news

Pfizer Faces Regulatory Action From Australian Government
Drug industry giant Pfizer is now facing regulatory action from the Australian government. The government’s competition regulator, the Australian Competition and Consumer Commission (ACCC) has said that Pfizer has illegally marketed the cholesterol drug Lipitor to Australian pharmacies, in direct violation of antitrust law. (Source: Pharmaceutical Online News)
Source: Pharmaceutical Online News - February 21, 2014 Category: Pharmaceuticals Source Type: news

Lipitor MDL News: Zoll, Kranz & Borgess Notes The Lipitor MDL Is...
The Firm is evaluating Lipitor lawsuits on behalf of individuals who allegedly developed Type 2 diabetes due to their use of Lipitor.(PRWeb February 20, 2014)Read the full story at http://www.prweb.com/releases/2014/02/prweb11601175.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - February 20, 2014 Category: Pharmaceuticals Source Type: news

Lipitor Lawsuits Involving Type 2 Diabetes Consolidated in South...
The Firm is evaluating Lipitor lawsuits on behalf of individuals who allegedly suffer from Type 2 diabetes due to their use of Lipitor.(PRWeb February 19, 2014)Read the full story at http://www.prweb.com/releases/lipitor-lawsuit/lipitor-diabetes/prweb11598721.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - February 20, 2014 Category: Pharmaceuticals Source Type: news

China Atorvastatin & Trastuzumab Market with 2018 Forecasts in New...
ChinaMarketResearchReports.com adds Latest Reports on Atorvastatin and Trastuzumab industry for China to its store.(PRWeb February 15, 2014)Read the full story at http://www.prweb.com/releases/atorvastatin-trastuzumab/china-market-reports/prweb11585316.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - February 16, 2014 Category: Pharmaceuticals Source Type: news

Lipitor Lawsuit News: Bernstein Liebhard Notes Recent Action Taken by...
The Firm is evaluating Lipitor lawsuits on behalf of individuals who allegedly developed Type 2 diabetes due to their use of Lipitor.(PRWeb February 13, 2014)Read the full story at http://www.prweb.com/releases/lipitor-lawsuit/lipitor-diabetes/prweb11583053.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - February 14, 2014 Category: Pharmaceuticals Source Type: news

NICE publishes new draft guidelines on statins use
"Millions more people should be put on cholesterol-lowering statin drugs," BBC News reports. Draft guidance from the National Institute for Health and Care Excellence (NICE) has recommended that the drugs should be given to people with an estimated 1 in 10 or more risk of cardiovascular disease (CVD), which includes conditions such as heart disease and stroke. Statins are medicines that can help lower rates of low-density lipoprotein (LDL) cholesterol (so-called "bad" cholesterol) in the blood. High rates of LDL cholesterol can lead to hardening of the arteries, a risk factor for CVDs. At present,...
Source: NHS News Feed - February 12, 2014 Category: Consumer Health News Tags: Heart/lungs Medication QA articles Source Type: news

Lipitor Lawsuit Hearing Rescheduled for February after Winter Weather...
The attorneys at Bernstein Liebhard LLP are investigating claims by potential Lipitor lawsuit claimants who may have developed Type 2 diabetes after taking the cholesterol-lowering statin.(PRWeb February 02, 2014)Read the full story at http://www.prweb.com/releases/lipitor-lawsuit/lipitor-diabetes/prweb11544689.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - February 3, 2014 Category: Pharmaceuticals Source Type: news

Lipitor Lawsuits Move Forward, with Federal Judicial Panel Set to...
The Firm is investigating Lipitor lawsuits on behalf of individuals who developed Type 2 diabetes, allegedly due to their use of the statin medication.(PRWeb January 28, 2014)Read the full story at http://www.prweb.com/releases/lipitor-lawsuit/lipitor-diabetes/prweb11530077.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - January 29, 2014 Category: Pharmaceuticals Source Type: news

New guidelines for taking cholesterol-lowering drugs target cardiovascular risk, not cholesterol level
For years, doctors prescribed the cholesterol-lowering drugs known as statins based largely on cholesterol test results. But new guidelines from the American Heart Association and the American College of Cardiology propose a major change to that strategy, reports the February 2014 Harvard Heart Letter. "The new guidelines shift away from a target-driven approach to a risk-driven approach," says Dr. Reena Pande, a cardiologist at Harvard-affiliated Brigham and Women's Hospital and an instructor in medicine at Harvard Medical School. Instead of striving to reach a specific cholesterol value, doctors should consider a person'...
Source: New Harvard Health Information - January 27, 2014 Category: Consumer Health News Source Type: news

All Lots of Liptruzet in U.S. Recalled Over Packaging Defect (FREE)
By Larry Husten All lots of the combination cholesterol-lowering drug Liptruzet (ezetimibe and atorvastatin) in the U.S. are being recalled because a packaging defect could … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - January 15, 2014 Category: Primary Care Source Type: news

Lipitor Lawsuit News: Pfizer, Inc. Named in Whistleblower Lawsuit...
The Firm is investigating Lipitor lawsuits on behalf of patients who developed Type 2 diabetes, allegedly due to Lipitor.(PRWeb January 14, 2014)Read the full story at http://www.prweb.com/releases/lipitor-lawsuit/lipitor-diabetes/prweb11488510.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - January 15, 2014 Category: Pharmaceuticals Source Type: news